Harmony Biosciences Holdings (HRMY) Cash from Operations Growth (1y) (2020 - 2026)

Harmony Biosciences Holdings (HRMY) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 7.14%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 356.73%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 3.23%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Harmony Biosciences Holdings 2.09 Bn 1.57 Bn 170.88 Mn -18.32%

Historic Data

Download Data
DateValue
Mar 31, 2026 -18.32%
Dec 31, 2025 66.95%
Sep 30, 2025 54.23%
Jun 30, 2025 86.14%
Mar 31, 2025 9.14%
Dec 31, 2024 -1.44%
Sep 30, 2024 11.73%
Jun 30, 2024 14.99%
Mar 31, 2024 -26.83%
Dec 31, 2023 187.37%
Sep 30, 2023 14.30%
Jun 30, 2023 9.88%
Mar 31, 2023 47.51%
Dec 31, 2022 -28.92%
Sep 30, 2022 81.45%
Jun 30, 2022 86.67%
Mar 31, 2022 130.26%
Dec 31, 2021 273.57%
Sep 30, 2021 244.24%
Jun 30, 2021 273.97%